Article
Fort Lauderdale, FL-The FDA has given GMP Companies Inc. its approval to expand a phase III clinical trial of its Eyepass glaucoma implant.
Making the grade: FDA approves first biosimilar product for retinal diseases
Advancement in TED treatment is a bright spot
Comparable conscious sedation methods address individual patient needs
Investigators uncover health care disparities among US patients
Investigators zoom in on future of dry eye treatment
Analyzing opioid prescription patterns of US retina specialists